Dr. Habil Khorakiwala,
Founder Chairman of Wockhardt
“Wockhardt Group, a research based Global Pharmaceutical and Biotech major, sets up its first facility in Middle East for manufacturing of NCEs (New Chemical Entities) catering to the global markets through its Dubai arm of its subsidiary Wockhardt Bio AG.” With an aim to grow and further establish their international presence in pharmaceutical manufacturing, Wockhardt inaugurated a ‘state-ofthe-art’ manufacturing facility for the production and packaging of sterile dry powder injection in Dubai. On approval of the new drug by US FDA, this manufacturing facility will be commissioned for commercial production. During the inauguration of the new facility, Dr. Habil Khorakiwala, Founder Chairman of Wockhardt said, “Wockhardt is poised for a quantum leap into the future. It is a future of dynamic changes, exciting possibilities and endless potential to further its goal of ‘Life Wins’ and Wockhardt is committed to shaping this future. With Wockhardt’s commitment to R&D, we have 5 breakthrough New Chemical Entities (NCEs) that have been accorded Qualified Infectious Disease Product (QIDP) status by US FDA. With the new facility in Middle East, we aim to focus on our commitment in developing NCEs to fight the health issues faced.” Antimicrobial resistance (AMR) - the ability of infections to resist antibiotics to work against it is increasingly recognized as growing global health problem. Infections caused by antimicrobial resistant strains of bacteria-also called “superbugs” are unlikely to respond to standard treatments resulting in prolonged illness and a greater risk to health, and severely impacting clinical outcomes, leading to further higher healthcare costs due to consumption of healthcare resources. Wockhardt currently has 5 novel antibiotic drugs in advanced stages of global clinical development which will be effective against these “superbugs” threats identified by the Center of Disease Control, USA. Considering the strategic importance of these antibiotics, the US FDA has granted Qualified Infectious Disease Program (QIDP) status to the 5 novel antibiotic drugs. “Wockhardt has dedicated significant resources for the discovery and development of novel antibiotics. These novel drugs in advanced stages of global development are a culmination of 20 years of dedicated and focused research in the antibiotics therapy segment with an aim to improve the quality of life”, said Dr. Murtaza Khorakiwala, Managing Director of Wockhardt. “The facility will work on the exhibit batches and will be offered for inspection by the regulators at an appropriate time”, he further added. Dr. Mahesh Patel, Chief Scientific Officer of New Drug Discovery, Wockhardt further added,
“Wockhardt’s drug discovery program has immensely benefitted from global collaborations with universities and scientists of international repute in the areas of public health, Infectious diseases and clinical microbiology”. “Wockhardt conducted extensive studies for identifying a region in the Middle East to establish a strong manufacturing presence for its advanced patented drugs. JAFZA was found to be appropriate for the factory premises for manufacturing patented proprietary drugs for global markets”, added Dr. Habil Khorakiwala. Wockhardt Bio AG manufacturing facility is designed to meet standards of various international regulatory agencies and the standards as set by the Local Ministry of Health. The facility meets the needs of Aseptic Dry Powder Inject able manufacturing and filling with a high quality operation. This facility is dedicated to launch its novel New Chemical Entities in the Antibiotics segment to the world from UAE. The facility is spread over 10,000 sq. meters of space, self-sufficient for handling Warehousing, Manufacturing Operations, Product Testing and Product Stability. The facility is equipped with bestin-class and fully automated manufacturing equipments and clean utility systems. The design takes into account the requirements for Product & Personnel Safety and Product Quality with complete close transfers and high levels of sterility assurances. About Wockhardt: Wockhardt is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. Wockhardt is a true Indian MultiNational Company with a multiethnic workforce of 8600 Wockhardt Associates from 21 different nationalities globally. It has 3 research centres and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Biopharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. New Wockhardt. New way of thinking Wockhardt is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and technoinnovation within Wockhardt. At Wockhardt, we are looking at new ways of thinking, new ways of working and new ways to touch people’s lives. Building a new Wockhardt Wockhardt’s Founder Chairman and Group CEO, Dr. Habil Khorakiwala says, “A decade ago, I saw a changing world that I believed would present us with large-scale future opportunities in the field of pharmaceuticals and biotechnology. We steered our business model to leverage our research capabilities in providing innovative solutions and by constantly upgrading our world-class manufacturing facilities. We ventured outside India systematically and positioned ourselves mainly in the European and the US markets, which currently generates over 76% of our revenues.” Growing presence around the world Head-quatered in Mumbai, India, Wockhardt has full-fledged operations in the USA, UK, Ireland and France. It also has its marketing presence in emerging markets of Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. Spearheading Research & Development Wockhardt’s core business is innovation. It uses science and technology to develop medicines and other products that improve the quality of millions people’s lives through better health. Wockhardt has proved its technical excellence by developing patented modified release formulations and recombinant biotechnology products. It has a multi-disciplinary R&D programme with more than 607 scientists, including over 80 doctorates, in the areas of:
Pharmaceutical Research Biotechnology & Genomics
Research
Novel Drug Delivery Systems
New Drug Discovery
Programme. API Research
Intellectual Property Wockhardt is in the forefront of Intellectual Property creation with 1,733 patents filed till date, of which 228 patents have been granted. Our capability and commitment in pursuing Intellectual Property has been recognised by the Government of India for four years in a row, with an award for the maximum number of ‘Patent filings and Grants from India’. Wockhardt is determined to create benchmarks for a promising future.